Evidence map›Paper›PMID 31602326›Full record

ArticleJournal of gastrointestinal oncology2019

Effect of

Ayman Rasmy, Alaa Fayed, Ayman Omar, Nermin Fahmy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ayman RasmyMedical Oncology, Zagazig University Hospitals, Zagazig, Egypt.
Alaa FayedClinical Oncology Department, Zagazig University, Zagazig, Egypt.
Ayman OmarClinical Oncology and Nuclear Medicine Department, Suez Canal University, Ismailia, Egypt.
Nermin FahmyClinical Oncology and Nuclear Medicine Department, Suez Canal University, Ismailia, Egypt.
Suez Canal University · EGZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNowadays, the outcomes of metastatic colorectal cancer (mCRC) have considerably improved. Genetic studies evaluating

methodsThis multicenter retrospective study evaluated 360 patients with mCRC treated at three oncology centers in Saudi Arabia and Egypt between February 2011 and December 2015. Patients were treated with bevacizumab and cetuximab according to guidelines. Therapy outcome, time to progression, and disease-associated death were assessed.

resultsApproximately 220 (61.1%) cases were of wild-type

conclusionsA major association between

Indexed as

Colorectal cancer (CRC)KRASmolecular studyoverall survival (OS)prognostic and predictive factors chemotherapy/target therapyprogression-free survival (PFS)

Identifiers

PMID31602326
PMCPMC6776817
OpenAlexW2946113593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.